Dr. Michael Pearl Discusses Palliative Care

Video

Dr. Michael Pearl breaks down the differences between palliative care and hospice care and explains the New York Palliative Care Information Act in this recording of his recent webinar, “Palliative Care for Women with Cancer.” Dr. Pearl is Professor and Director of the Division of Gynecologic Oncology in the Department of Obstetrics, Gynecology and Reproductive Medicine at Stony Brook University Hospital. Watch it below.

SHARE Webinar: Palliative Care for Women with Cancer from SHARE on Vimeo.

Recent Videos
Susan Sabo-Wagner, MSN, RN, OCN, NEA-BC in an interview with oncology nursing news
Anne M. Reb, PhD, NP, discussing a nurse-led intervention for fear of cancer recurrence.
Ann H. Partridge, MD, MPH, in an interview with Oncology Nursing News at 2024 ESMO Congress.
Elizabeth Burton in an interview with Oncology Nursing News
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
image of brain representing central nervous system

Larotrectinib Is Promising for Pediatric TRK Fusion-Positive CNS Tumors

Ryan Scott
November 26th 2024
Article

Larotrectinib led to rapid/durable responses and high disease control rates in children with TRK fusion-position central nervous system cancers.

The Vitals

What New Cancer Drugs Were Approved in 2023?

Lindsay Fischer
January 1st 2024
Podcast

In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.

breast on yellow background

Cancer Vaccine Sparks Immune Response in TNBC

Jordyn Sava
November 25th 2024
Article

Most patients with triple-negative breast cancer experienced a protocol-defined immune response with an investigational vaccine, phase 1 data showed.

The Vitals

Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

Lindsay Fischer
December 14th 2023
Podcast

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

gynecologic system on light blue background

Consider BRCA, HRD Status Before Deciding on a PARP Inhibitor for Ovarian Cancer

Ashling Wahner
November 23rd 2024
Article

PARP inhibitors have changed the way we think about [managing] ovarian cancer,” Whitney Goldsberry, MD, said

prostate on a yellow background

FDA Accepts New Drug Application to Darolutamide Plus ADP for mHSPC

Chris Ryan
November 22nd 2024
Article

The FDA accepted a supplemental new drug application to darolutamide plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer.

© 2024 MJH Life Sciences

All rights reserved.